Phathom Pharmaceuticals currently holds 89.67
M in liabilities with Debt to Equity (D/E) ratio of 2.43, implying Phathom Pharmaceuticals greatly relies on financing operations through barrowing.
Our trade recommendations tool can cross-verify current
analyst consensus on Phathom Pharmaceuticals and to analyze the firm potential to grow in the current economic cycle.
We determine the current worth of Phathom Pharmaceuticals using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Phathom Pharmaceuticals based exclusively on its
fundamental and basic
technical indicators. By analyzing Phathom Pharmaceuticals's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Phathom Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Phathom Pharmaceuticals. We calculate exposure to Phathom Pharmaceuticals's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Phathom Pharmaceuticals's related companies.
Phathom Pharmaceuticals Investment Alerts
Phathom investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Phathom Pharmaceuticals performance across your portfolios.Please check all
investment alerts for Phathom
Phathom Pharmaceuticals Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Phathom value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Phathom Pharmaceuticals competition to find
correlations between indicators driving the intrinsic value of Phathom.
Phathom Pharmaceuticals Gross Profit
Phathom Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Phathom Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Phathom Pharmaceuticals Gross Profit growth over the last 10 years. Please check Phathom Pharmaceuticals'
gross profit and other
fundamental indicators for more details.
Breaking down Phathom Pharmaceuticals Indicators
Net Loss for the year was (143.88
M) with profit before overhead, payroll, taxes, and interest of 0.
Phathom Pharmaceuticals Earnings Before Interest Taxes and Depreciation Amortization EBITDA is comparatively stable at the moment. Phathom Pharmaceuticals Cash Flow Per Share is comparatively stable at the moment. Additionally, Phathom Pharmaceuticals Long Term Debt to Equity is increasing over the last 5 years. The newest value of Phathom Pharmaceuticals Long Term Debt to Equity is 1.21. Phathom Pharmaceuticals Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 6 years. Phathom Pharmaceuticals Cash Flow Per Share is decreasing over the last 5 years. The previous year's value of Phathom Pharmaceuticals Cash Flow Per Share was -6.04. Additionally, Phathom Pharmaceuticals Long Term Debt to Equity is increasing over the last 5 years. The previous year's value of Phathom Pharmaceuticals Long Term Debt to Equity was 1.21.
Our perspective of the newest Phathom Pharmaceuticals gain
The expected short fall is down to -4.92 as of today.
As of the 28th of January, Phathom Pharmaceuticals holds the Coefficient Of Variation of 1087.05,
risk adjusted performance of 0.1074, and Semi Deviation of 6.62. Compared to
fundamental indicators, the
technical analysis model allows you to check existing technical drivers of Phathom Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze nineteen
technical drivers for Phathom Pharmaceuticals, which can be compared to its competitors. Please check
Phathom Pharmaceuticals standard deviation, as well as the
relationship between the maximum drawdown and
expected short fall to decide if Phathom Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 12.36 per share. Given that Phathom Pharmaceuticals has
jensen alpha of 0.3848, we recommend you to check out Phathom Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.
Whereas other companies under the biotechnology industry are still a bit expensive, Phathom Pharmaceuticals may offer a potential longer-term growth to private investors. On the whole, as of the 28th of January 2023, we see that Phathom Pharmaceuticals actively responds to the market. The firm is
undervalued with
close to average odds of financial turmoil within the next 24 months. Our ongoing 90 days recommendation on the firm is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Phathom Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
